Indole Compounds Activate PI3K Pathway for Wound Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic wounds, such as Becaplermin, have limitations including short half-life in protease-rich wound environments and inadequate delivery mechanisms, necessitating the development of growth factor pathway activators that can bypass downregulated receptors and offer increased stability with no immunogenic risk.
Innovation Solution
The disclosure provides indole compounds and their pharmaceutically acceptable salts that activate the PI3K/Akt/mTOR pathway, potentially promoting wound healing and tissue repair by directly stimulating cellular processes without relying on growth factor receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant PDGF is used to treat chronic wounds, then wound healing is promoted, but the treatment has short half-life in protease-rich wound environments
Solution Approach 1:
The patent uses downstream signaling molecules (Akt, mTOR, and their inhibitors) as intermediaries to transmit the growth factor signal without requiring the presence of growth factors themselves. This mediator approach bypasses the instability issue of growth factors in protease-rich environments while still achieving the desired wound healing effect through the same signaling pathway.
Solution Approach 2:
The patent extracts the essential signaling function from the growth factor molecule itself, separating the signal transmission capability from the unstable growth factor protein. By using small molecule inhibitors of downstream targets (Akt, mTOR) as proxies, the patent removes the problematic growth factor while retaining the therapeutic effect.
2Reliability
If recombinant growth factors are used to treat chronic wounds, then tissue repair is enhanced, but delivery mechanisms are inadequate
Solution Approach 1:
The patent replaces the complex mechanical delivery system required for recombinant growth factors (which requires controlled release, stabilization, and targeted delivery) with simple small molecule compounds that can be delivered through conventional topical or systemic administration. This substitution eliminates the need for sophisticated delivery mechanisms.
3Reliability
If growth factor receptors are used in chronic wound treatment, then cellular response is stimulated, but receptor density is decreased in chronic wounds
Solution Approach 1:
Instead of trying to stimulate receptors that are downregulated in chronic wounds, the patent inverts the approach by acting downstream in the signaling pathway. By using Akt and mTOR inhibitors, the patent bypasses the depleted receptor level and directly modulates the signaling cascade at later stages where receptor density is irrelevant.
4Productivity
If recombinant growth factors are used for wound healing, then healing is accelerated, but immunogenicity risk increases
Solution Approach 1:
The patent employs small molecule compounds as disposable, non-immunogenic alternatives to recombinant growth factors. These small molecules can be administered repeatedly without eliciting immune responses, allowing sustained treatment of chronic wounds without the immunogenicity constraints that limit growth factor therapy.
Data Source
AI summary
The present disclosure provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, and its therapeutic uses for activating a growth factor pathway, promoting wound healing, promoting tissue repair, and treating hearing loss, skeletal muscle loss, organ degeneration, tissue damage, neurodegeneration, and muscular atrophy. The disclosure further provides pharmaceutical compositions and combinations. The present disclosure also relates to the use of such compounds for research or other non- therapeutic purposes.